You are here: Industry Insights > Celgene

News List

Bristol-Myers $74bn Celgene takeover gets shareholders approvals pharmaceutical-technology
April 23, 2019
Bristol-Myers $74bn Celgene takeover gets shareholders approvals...
BMS, Celgene shareholders back mega merger pharmatimes
April 16, 2019
Bristol-Myers Squibb has announced the backing of its Celgene merger by shareholders……
Bristol-Myers Squibb shareholders approve Celgene acquisition worldpharmanews
April 16, 2019
Bristol-Myers Squibb shareholders approve Celgene acquisition.
Bristol-Myers Squibb, Celgene shareholders vote to back proposed $74-billion merger firstwordpharma
April 14, 2019
Shareholders have voted to approve Bristol-Myers Squibb's roughly $74-billion deal to acquire Celgene, the companies announced separately on Friday.
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA drugs
April 11, 2019
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA.
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis drugs
April 11, 2019
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis.
Celgene seeks FDA approval for luspatercept to treat anaemia pharmaceutical-technology
April 09, 2019
Celgene seeks FDA approval for luspatercept to treat anaemia
Celgene receives positive CHMP opinion for lenalidomide and pomalidomide for multiple myeloma patients biospectrumasia
April 02, 2019
The committee also recommended approval of IMNOVID in combination with bortezomib and dexamethasone (PVd)……
Celgene resubmits MS drug, ozanimod, to FDA pharmatimes
March 28, 2019
After a failed attempt in 2017, Celgene has decided to refile its relapsing remitting multiple sclerosis (RRMS) drug, ozanimod, with the US Food and Drug Administration (FDA).
Without 'smoking gun,' BMS, Celgene deal will close as planned: analyst fiercepharma
March 20, 2019
Despite staunch disagreement over the merits of the merger, at least one analyst still believes the deal will go through after a vote on April 12.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page